Yes, Call It A Comeback: Amicus Fabry Drug Posts Big Study Win

CRANBURY, NJ (TheStreet) -- Amicus Therapeutics CEO John Crowley came close to permanentlyashelving his company's experimental Fabry disease therapyafollowing disappointing results from a late-stageastudy in December 2012 and the departure of partner GlaxoSmithKline about one year later. But Crowley -- famous for his perseverance -- decided to stick with the drug, migalastat, in the hope that a slower-to-enroll, second phase III study would resurrect chances for eventual approval.

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News